They may suggest a lower dose or lifestyle changes to mitigate the fluttering
APHD-012: Mimicking Gastric Bypass Effects APHD-012 is an innovative oral medication designed to mimic the metabolic effects of gastric bypass surgery, offering a less invasive alternative for weight loss and glucose control
WISEMAN: My advice for someone on a GLP-1 is not necessarily that different from someone who's not on a GLP-1
J.AspockC.SchullerC
Exclusion criteria included patients younger than 18 years, any patient with a death date on or before the index date (deceased patients at baseline), individuals with pre-existing conditions known to impact gastrointestinal GI functions, e.g., major GI or abdominal surgeries, connective tissue disorders (e.g., amyloidosis, Ehlers-Danlos syndrome, Sjgrens syndrome), inflammatory bowel diseases, and other major systemic or GI conditions (cystic fibrosis, intestinal failure, etc.) predisposing to SIBO
Your body may downregulate GLP-1 receptor density or increase receptor internalization, meaning the same dose stimulates fewer appetite-suppressing signals over time
